[Clinical study of recombinant human growth hormone for male climacteric syndrome].

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

To evaluate the effect and safety of the recombinant human growth hormone (rhGH) in the treatment of male climacteric syndrome and to investigate the specificity and sensitivity of insulin-like growth factor-1 (IGF-1) and serum total testosterone as the curative effect index.

Who Took Part

PubMed tags the participants as men only.

The serum IGF-1, total testosterone (TT) and prostatic specific antigen(PSA) were measured before and after the treatment.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

The data were analysed by the software of SPSS 12.0 for Windows.

What Was Measured

The subject headings attached to it are Andropause, Human Growth Hormone, Insulin-Like Growth Factor I, Prostate-Specific Antigen, Sensitivity and Specificity, Syndrome and Testosterone.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2005 (Zhonghua nan ke xue = National journal of andrology), a journal based in China.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.